ValuEngine downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

ORMP has been the subject of several other research reports. HC Wainwright set a $25.00 target price on shares of Oramed Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, June 6th. B. Riley downgraded shares of Oramed Pharmaceuticals from a buy rating to a neutral rating in a report on Monday, July 16th.

ORMP stock opened at $4.95 on Tuesday. Oramed Pharmaceuticals has a one year low of $4.60 and a one year high of $11.34. The firm has a market capitalization of $88.90 million, a PE ratio of -6.27 and a beta of 0.35.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its earnings results on Thursday, July 12th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.03). Oramed Pharmaceuticals had a negative return on equity of 63.20% and a negative net margin of 204.00%. The firm had revenue of $0.62 million during the quarter, compared to analyst estimates of $0.61 million. equities research analysts expect that Oramed Pharmaceuticals will post -0.96 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. BlackRock Inc. purchased a new stake in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 28,041 shares of the biotechnology company’s stock, valued at approximately $209,000. BlackRock Inc. owned approximately 0.16% of Oramed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.52% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.

Further Reading: Dividend Stocks – Are They Right For You?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.